Shares of Juno Ther­a­peu­tics plunged more than 27% Fri­day, a day af­ter halt­ing a mid­stage study on a po­ten­tial leukemia treat­ment fol­low­ing two patient deaths.

Modern Healthcare - - LATE NEW -

The de­vel­op­mentstage biotech­nol­ogy com­pany is work­ing on JCAR015 as a treat­ment for a type of leukemia. It is the com­pany’s most ad­vanced drug can­di­date and there­fore the most vis­i­ble in­di­ca­tor of progress for in­vestors. The Seat­tle-based com­pany said last week that the study has been put on hold af­ter it added the chemo­ther­apy drug flu­dara­bine to the reg­i­men. It has pro­posed con­tin­u­ing the study with­out flu­dara­bine. Juno’s shares have fallen al­most 40% over the past year.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.